These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29862971)

  • 1. Immunotherapy-induced hypothyroidism A report of melanoma treated by ipilimumab and nivolumab.
    Haissagerre M; Prey S; Lauro C; Rousset M; Georges A; Corcuff JB
    Ann Biol Clin (Paris); 2018 Jun; 76(3):326-328. PubMed ID: 29862971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
    Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Thyroperoxidase Antibody Levels >500 IU/ml Indicate a Moderately Increased Risk for Developing Hypothyroidism in Autoimmune Thyroiditis.
    Ehlers M; Jordan AL; Feldkamp J; Fritzen R; Quadbeck B; Haase M; Allelein S; Schmid C; Schott M
    Horm Metab Res; 2016 Sep; 48(10):623-629. PubMed ID: 27607246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
    J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.
    Mehta A; Gupta A; Hannallah F; Koshy T; Reimold S
    Melanoma Res; 2016 Jun; 26(3):319-20. PubMed ID: 27110676
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroid function and prevalence of anti-thyroperoxidase (TPO) and anti-thyroglobulin (Tg) antibodies in outpatients hospital setting in an area with sufficient iodine intake: influences of age and sex.
    Legakis I; Manousaki M; Detsi S; Nikita D
    Acta Med Iran; 2013; 51(1):25-34. PubMed ID: 23456581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune mediated neuropathy following checkpoint immunotherapy.
    Gu Y; Menzies AM; Long GV; Fernando SL; Herkes G
    J Clin Neurosci; 2017 Nov; 45():14-17. PubMed ID: 28765062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
    Cao Y; Afzal MZ; Shirai K
    BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of shortened infusion times for combined ipilimumab and nivolumab.
    Gassenmaier M; Lipp HP; Scheu A; Wagner NB; Kofler L; Mueller A; Doecker D; Eigentler TK; Garbe C; Forschner A
    Cancer Immunol Immunother; 2018 Jan; 67(1):135-140. PubMed ID: 28988363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclinical hypothyroidism and autoimmune thyroiditis in pregnancy--a study in south Indian subjects.
    Gayathri R; Lavanya S; Raghavan K
    J Assoc Physicians India; 2009 Oct; 57():691-3. PubMed ID: 20329425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK; Watson DE
    Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.
    Bossart S; Thurneysen S; Rushing E; Frontzek K; Leske H; Mihic-Probst D; Nagel HW; Mangana J; Goldinger SM; Dummer R
    Oncologist; 2017 Jun; 22(6):749-753. PubMed ID: 28559410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
    Barone A; Hazarika M; Theoret MR; Mishra-Kalyani P; Chen H; He K; Sridhara R; Subramaniam S; Pfuma E; Wang Y; Li H; Zhao H; Zirkelbach JF; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Oct; 23(19):5661-5665. PubMed ID: 28179454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
    Jotatsu T; Oda K; Yamaguchi Y; Noguchi S; Kawanami T; Kido T; Satoh M; Yatera K
    Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of antigenic epitopes of thyroperoxidase, thyroglobulin and interleukin-24. Exploration of cross-reactivity with environmental allergens and possible role in urticaria and hypothyroidism.
    Sánchez A; Cardona R; Munera M; Sánchez J
    Immunol Lett; 2020 Apr; 220():71-78. PubMed ID: 32027873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.